Adaptyv

We're building fully automated labs for protein engineering

Lausanne, Switzerland · Founded 2021 · $10.8M raised

Headquarters
Lausanne
Employees
11–50
Founded
2021
Total Funding
$10.8M
Last Round
$8.0M SeedJan 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Proteins are the most advanced nanotechnology we know of. At Adaptyv, our mission is to make proteins easier to engineer. We are building technologies that allow protein engineers to design and test new proteins in order to develop new medicines, better enzymes for research and industrial application or functional materials with novel properties.

Summary

Adaptyv is a Drug Discovery company based in Lausanne, Switzerland, founded in 2021. It has raised $10.8M in total across 3 rounds, most recently a $8.0M Seed round in Jan 2024. Investors include ACE Ventures, Wingman Ventures and Y Combinator.

Tech & App Stack

17 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed Round2024 (est.)
$8.0M

Sign up to see all 3 events

Funding: Pre-Seed through Seed. Amounts, valuations, and investors where available.

Investors

Similar Companies

Shields Health Solutions

The nation's first company to integrate specialty pharmacies into hospitals and health systems, h...

United StatesHealthcare, Drug Discovery
Corporate RoundTotal funding$3.5BSep 2025
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
H.C. Starck

German specialty materials company producing high-quality tungsten powders and refractory metal s...

Goslar, Germany1001–5000Manufacturing, Healthcare
Private EquityTotal funding$908.0MJan 2007

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adaptyv on Indexed.vc
<a href="https://indexed.vc/companies/adaptyvbio"><img src="https://indexed.vc/api/badge/company/adaptyvbio" alt="Adaptyv on Indexed.vc" width="260" height="76" /></a>